The balANZ study--strengthening the evidence for neutral-pH solutions low in glucose degradation products

about

The balANZ study--strengthening the evidence for neutral-pH solutions low in glucose degradation products

Item

http://www.wikidata.org/entity/Q36474231

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

The balANZ study--strengthenin ...... n glucose degradation products

@ast

The balANZ study--strengthenin ...... n glucose degradation products

@en

type

Item

label

The balANZ study--strengthenin ...... n glucose degradation products

@ast

The balANZ study--strengthenin ...... n glucose degradation products

@en

prefLabel

The balANZ study--strengthenin ...... n glucose degradation products

@ast

The balANZ study--strengthenin ...... n glucose degradation products

@en

P1476

The balANZ study--strengthenin ...... n glucose degradation products

@en

P2093

Martin Wilkie

http://www.w3.org/2001/XMLSchema#string

P2860

Grading quality of evidence and strength of recommendations

Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription.

The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: benefit at bench, bedside, or both?

Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.

Intraperitoneal IL-6 signaling in incident patients treated with icodextrin and glucose bicarbonate/lactate-based peritoneal dialysis solutions.

Trials (and tribulations) of biocompatible peritoneal dialysis fluids

A well-conducted randomized trial that establishes no benefit of therapy is an important medical advance.

Public involvement at the design stage of primary health research: a narrative review of case examples.

ISPD position statement on reducing the risks of peritoneal dialysis-related infections.

Glucose degradation products in peritoneal dialysis fluids: how they can be avoided.

P304

489-492

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/PDI.2012.00204

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22991013

http://www.w3.org/2001/XMLSchema#string

P921

glycobiology

P932

3524862

http://www.w3.org/2001/XMLSchema#string